What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Prevalence of colistin resistance in clinical isolates ofFrontiers in microbiology · 2024
   Pooled it
2. Current and future options for the treatment of serious infections due to carbapenem-resistantClinical microbiology reviews · 2025
   Review
3. Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis.Current therapeutic research, clinical and experimental · 2024
   Review
4. Antibiotic Therapy Strategies for Treating Gram-Negative Severe Infections in the Critically Ill: A Narrative Review.Antibiotics (Basel, Switzerland) · 2023
   Review
5. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
   Article
6. New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.Antimicrobial agents and chemotherapy · 2022
   Review
7. New Drugs for the Treatment ofAntibiotics (Basel, Switzerland) · 2022
   Review
8. Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.Drugs · 2022
   Review
9. Imipenem-Relebactam Susceptibility and Genotypic Characteristics of Carbapenem-ResistantAntimicrobial agents and chemotherapy · 2021
   Article
10. Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.Drugs · 2021
    Review
11. Susceptibility to Imipenem/Relebactam ofInfection and drug resistance · 2021
    Article
12. New β-Lactam-β-Lactamase Inhibitor Combinations.Clinical microbiology reviews · 2020
    Review
13. Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020
    Review
14. The Strategies of Pathogen-Oriented Therapy on Circumventing Antimicrobial Resistance.Research (Washington, D.C.) · 2020
    Review
15. A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date.Infection and drug resistance · 2020
    Review
16. The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.Expert opinion on pharmacotherapy · 2019
    Review
17. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections.Clinical microbiology reviews · 2019
    Review
18. Antimicrobial agents and chemotherapy · 2019
    Article
19. Carbapenem-NonsusceptibleJournal of clinical microbiology · 2019
    Article
20. A Combination Antibiogram Evaluation forAntimicrobial agents and chemotherapy · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as